The Role of Finerenone in Optimizing Cardiovascular-Kidney-Metabolic Health: Everything PCPs Should Know

Cardiovascular, kidney, and metabolic (CKM) syndrome is a complex health disorder attributable to the substantial overlap and connections among obesity, diabetes, chronic kidney disease, and cardiovascular disease resulting from shared risk factors, and interconnected, interdependent pathophysiology. Primary care professionals (PCPs) should detect CKM syndrome early and aggressively treat all patients who are at risk. Nonsteroidal mineralocorticoid receptor antagonists like finerenone can favorably affect the progression of CKM syndrome at each stage. PCPs should become familiar with the benefits of a 4-pillar approach across different management phases of CKM syndrome.